Next Article in Journal
The Extremely-Low-Frequency Electromagnetic Field Affects Apoptosis and Oxidative-Stress-Related Genes and Proteins in the Porcine Endometrium—An In Vitro Study
Previous Article in Journal
Comprehensive Characterization of Phytochemical Composition, Membrane Permeability, and Antiproliferative Activity of Juglans nigra Polyphenols
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 13
10.3390/ijms25136922
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis

by
Nema A. Mohamed
1,†,
Mohammed T. Ithmil
1,2,†,
Ayman I. Elkady
1 and
Sherine Abdel Salam
1,3,*
1
Department of Zoology, Faculty of Science, Alexandria University, Alexandria 21511, Egypt
2
Department of Biology, Faculty of Science, Al-Mustansiriya University, Baghdad P.O. Box 14022, Iraq
3
Department of Biological Sciences, Faculty of Science, King Faisal University, P.O. Box 380, Al-Ahsa 31982, Saudi Arabia
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2024, 25(13), 6922; https://doi.org/10.3390/ijms25136922
Submission received: 30 April 2024 / Revised: 31 May 2024 / Accepted: 8 June 2024 / Published: 25 June 2024
(This article belongs to the Section Molecular Biology)
Browse Figures
Versions Notes

Abstract

:
Tauroursodeoxycholic acid (TUDCA) is approved for the treatment of liver diseases. However, the antihyperglycemic effects/mechanisms of TUDCA are still less clear. The present study aimed to evaluate the antidiabetic action of TUDCA in streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM) in rats. Fifteen adult Wistar albino male rats were randomly divided into three groups (n = five in each): control, diabetic (STZ), and STZ+TUDCA. The results showed that TUDCA treatment significantly reduced blood glucose, HbA1c%, and HOMA-IR as well as elevated the insulin levels in diabetic rats. TUDCA therapy increased the incretin GLP-1 concentrations, decreased serum ceramide synthase (CS), improved the serum lipid profile, and restored the glycogen content in the liver and skeletal muscles. Furthermore, serum inflammatory parameters (such as TNF-α, IL-6, IL-1ß, and PGE-2) were substantially reduced with TUDCA treatment. In the pancreas, STZ+TUDCA-treated rats underwent an obvious enhancement of enzymatic (CAT and SOD) and non-enzymatic (GSH) antioxidant defense systems and a marked decrease in markers of the lipid peroxidation rate (MDA) and nitrosative stress (NO) compared to STZ-alone. At the molecular level, TUDCA decreased the pancreatic mRNA levels of iNOS and apoptotic-related factors (p53 and caspase-3). In conclusion, TUDCA may be useful for diabetes management and could be able to counteract diabetic disorders via anti-hyperlipidemic, antioxidant, anti-inflammatory, and anti-apoptotic actions.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a complex endocrine and metabolic disorder, which is characterized by deficient insulin secretion, insulin resistance (IR), and/or pancreatic islet β-cell failure to maintain normoglycemia [1]. In particular, T2DM is becoming a global challenge that affects millions of people of all ages, sex, race, and ethnic groups [2]. T2DM has been reported to be associated with serious complications, including retinopathy, nephropathy, liver damage, and cardiovascular diseases [3]. Evidence in the literature has indicated that under the T2DM condition, proinflammatory cytokines and chemokines increase, which also initiate oxidative stress through excessive production of reactive oxygen and/or nitrogen species (ROS/RNS) [4]. Furthermore, oxidative stress overload can compromise ß-cell function, trigger apoptotic cell death, and ultimately may lead to a progressive loss of ß-cell mass [5]. Therefore, the use of natural antioxidants as complementary or adjunct therapies can offer new avenues for the prevention and even treatment of T2DM. Tauroursodeoxycholic acid (TUDCA) is an endogenous bile acid derivative that has been documented to be clinically effective in the treatment of cholestatic liver disorders [6]. TUDCA has also been reported to improve inflammatory metabolic diseases such as atherosclerotic progression, persistent hyperglycemia associated with both types of diabetes, and kidney failure [7]. Furthermore, TUDCA has demonstrated anti-apoptotic properties in a number of neurological injuries [8,9]. Recently, TUDCA treatment was reported to reduce glucose homeostasis disturbance in streptozotocin (STZ)-induced Alzheimer’s disease pathology [10]. However, the precise mechanisms that regulate the potential antidiabetic effects of TUDCA remain elusive. Therefore, our objective was to assess the antidiabetic efficiency of TUDCA against STZ-induced T2DM in vivo while investigating the underlying biochemical/molecular mechanisms. Our results may have significant importance for the clinical translation of TUDCA as an adjunct therapeutic agent in the management of T2DM.

2. Results

2.1. TUDCA Improves Hyperglycemia in Diabetic Rats

As shown in Figure 1, TUDCA treatment elicited significantly higher blood glucose (Figure 1A), HbA1c% (Figure 1B), and HOMA-IR (Figure 1C) in STZ-induced diabetic rats compared to the control. Furthermore, there was a significant decrease in the insulin levels (Figure 2D) of diabetic rats compared to normal animals. However, all these values were reversed in STZ+TUDCA-treated rats compared to diabetic rats. The results indicated that the treatment of diabetic rats with TUDCA induced a marked decrease in glucose, HbA1c%, and HOMA-IR and increased insulin compared to the STZ group. In particular, TUDCA was effective in returning HOMA-IR to normalized control levels.

2.2. TUDCA Effects on Serum Incretin GLP-1, CS, and Liver/Muscle Glycogen in Diabetic Rats

Next, we found that incretin GLP-1 was lower in the serum of diabetic rats (Figure 2A), while CS was drastically higher (Figure 2B) than in the corresponding controls. Treatment with TUDCA in diabetic rats significantly increased the level of incretin GLP-1 and reduced the activity of CS compared to STZ-induced diabetic rats, with recovery to the control values. It was also noticed that the liver/muscle glycogen levels were in high decline (Figure 2C,D) in diabetic rats compared to normal animals. Treatment with TUDCA significantly increased glycogen in the liver and muscle of STZ+TUDCA-treated rats compared to the STZ-alone treated group, but the values remained below normal.

2.3. TUDCA Effects on Dyslipidemia in Diabetic Rats

The results obtained showed a statistically significant increase in the serum levels of TC (Figure 3A), TG (Figure 3B), LDL-C (Figure 3C), and VLDL-C (Figure 3D), while HDL-C significantly decreased (Figure 3E) in STZ-induced diabetic rats compared to the control values. Upon administration of TUDCA to STZ-treated rats, the levels of TC, TG, LDL-C, VLDL-C, and HDL-C were corrected relative to the STZ-alone group without reaching the normal levels.

2.4. TUDCA Effects on Proinflammatory Cytokines and PGE-2 in Diabetic Rats

Figure 4 depicts that there was a significant increase in the serum levels of proinflammatory TNF-α (Figure 4A), IL-6 (Figure 4B), IL-1β (Figure 4C), and PGE-2 (Figure 4D) in the diabetic group compared to the control. These key inflammatory factors significantly diminished in the STZ+TUDCA-treated rats compared to the STZ-induced diabetic rats. Specifically, TUDCA adequately reduced IL-1β down to the control values.

2.5. TUDCA Effects on Pancreatic Redox State in Diabetic Rats

Our data showed that STZ treatment resulted in significant depletions in pancreatic SOD (Figure 5A), CAT (Figure 5B), and GSH (Figure 5C) compared to the control group. TUDCA treatment significantly counteracted these decreased levels in diabetic rats but not to the control baseline levels. However, there were significant elevations in the levels of NO (Figure 5D) and MDA (Figure 5E) in the pancreas of diabetic rats compared to the healthy control group. TUDCA significantly reduced NO and MDA in diabetic animals but could not bring them to normal values.

2.6. TUDCA Effects on mRNA Expression of iNOS, p53, and Caspase-3 in Diabetic Rats

The qRT-PCR results showed that the diabetic group (STZ) induced a substantial up-regulation of mRNA in pancreatic iNOS (Figure 6A), p53 (Figure 6B), and caspase-3 (Figure 6C) compared to the control. However, the administration of TUDCA as therapy in STZ-induced diabetic rats resulted in a marked downregulation of these genes compared to STZ-treated animals. Notably, in the STZ+TUDCA group, the expression of all the tested genes declined to the control levels.

3. Discussion

TUDCA and its taurine-free precursor UDCA have been used to treat human liver diseases, usually in long-term (chronic) oral doses of 10–20 mg/kg/day [11,12]. Furthermore, protection by UDCA/TUDCA extends beyond the liver to other organs and targets in the body. Preclinical data in nondiabetic models (e.g., [13,14,15,16,17,18]) showed that high ip/iv doses of UDCA/TUDCA (up to 500 mg/kg/day), administered as single or short-term injections, were safe and well-tolerated for therapeutic use. The aim of the current work is to assess the hypoglycemic action of TUDCA in STZ-induced diabetic rats. STZ has been extensively used as a drug of choice to induce diabetes in animal experiments [19]. It was reported that low ip doses of STZ (40–50 mg/kg b.w.) result in the destruction of some of the population of β-cells in the pancreatic islets, and residual β-cells remain, which produce insufficient insulin, causing the T2DM model [20,21]. The mechanism of the STZ-induced diabetic state includes its selective cytotoxicity to β-cells, which makes cells less active, leading to poor insulin sensitivity to glucose uptake by tissues and hyperglycemia [22]. Pancreatic β-cells are extremely vulnerable to oxidative damage by NO and free radicals due to the relatively low activity of antioxidant enzymes in the tissue [23]. The current results demonstrated that ip administration of TUDCA at a dose of 300 mg/kg b.w. has an antidiabetic effect by lowering the levels of glucose, HOMA-IR, and HbA1c% and improving the levels of insulin and glycogen in the liver and muscle. In a previous study, 20 days of treatment of TUDCA (500 mg.kg/day, i.p.) established normoglycemia and modulated insulin resistance in the liver, skeletal muscle, and adipose tissue of genetically obese ob/ob mice [24]. Comparatively, the lower ip dose of TUDCA used in this research was previously found to be helpful for the control of hyperinsulinemia in obese pre-diabetic mice [25]. Moreover, in silico studies predicted that TUDCA may also act as an insulin receptor agonist, which, in addition, can contribute to beneficial effects on insulin sensitivity [26]. In this context, TUDCA has emerged as an important candidate for T2DM; however, we still do not understand the complete picture of the mechanisms of action of this bile acid on glycemic control. Our data indicated a normalizing effect of TUDCA on the STZ-induced inactivation of serum incretin GLP-1, which further supports the antihyperglycemic properties of TUDCA. Incretin hormones (GLP-1 and GIP) have been reported to enhance insulin release from the pancreas and have been shown to exert proliferative and anti-apoptotic effects on the β-cells [27]. Previously, in vitro and in vivo reports have already pointed to bile acids as potent stimulators of GLP-1 secretion [28,29,30]. As already reported, the pancreas contains (static) quiescent ß-cells, which have the capacity to regenerate; in turn, the surviving cells multiply to replace the lost cells [31]. Therefore, it is possible that TUDCA was also responsible for the proliferation of ß-cells and the recovery of the STZ-induced lowered insulin level. There are already reports showing other natural ingredients that have regenerative potential for ß-cells [21,32].
Furthermore, our results are the first demonstration that TUDCA significantly reduced CS in sera from STZ-induced diabetic rats. Serum CS has been linked to atherosclerotic lesions and immune-inflammatory states in experimental animals [33]. Emerging evidence has implicated the accumulation of cell-permeable ceramide in pancreatic β-cells as contributing to β-cell destruction [34]. Early reports indicate that ceramide sphingolipid inhibits insulin-stimulated glucose uptake, insulin gene transcription, and glycogen synthesis [35,36]. Ceramide induces the complex signaling machinery required for the cascade activation of caspases [37]. In addition, ceramide has been shown to target the mitochondrial membrane, resulting in ROS/RNS production and the activation of cell apoptosis [38]. The inhibition of Akt by ceramide is also proposed in the mechanisms by which ceramide causes β-cell apoptosis [39]. On the basis of the previous background, it is plausible to speculate that the anti-apoptotic action of TUDCA may be mediated by counteracting ceramide production. These results are consistent with a previous in vitro observation by Liu et al. [40].
In the current study, we also detected hyperlipidemia in STZ-induced diabetic rats. The aberrant lipid profile was evidenced by elevated levels of TC, TG, LDL, and VLDL and decreased HDL. The robust production of ROS (pro-oxidants) is another outcome of hyperlipidemia under diabetic conditions [41]. The findings of our study revealed that TUDCA treatment effectively combated hyperlipidemia by lowering TC, TG, LDL-C, and VLDL-C and by raising HDL-C in diabetic rats. This suggests that TUDCA has a lipid-lowering action, which can be attributed to an improvement in insulin secretion and subsequent reduction in the synthesis of TC and TG. Our results are in agreement with the reported findings of Cui et al. [42], who used different concentrations of TUDCA (25/50/100 mg/kg b.w.) orally to treat high fat-diet (HFD)-induced hyperlipidemic mice.
Furthermore, we have investigated the effect of TUDCA on key mediators implicated in the downregulation of oxidative stress in STZ-induced diabetic rats. The STZ-induced prolonged hyperglycemia is associated with high levels of free radicals, which can lead to harmful effects such as (i) increased lipid peroxidation, (ii) altered antioxidant status, and (iii) impaired glucose metabolism in biological systems [43]. The imbalance between these pro-oxidant molecules and endogenous antioxidants (i.e., oxidative stress) plays an important role in insulin resistance pathogenesis [44,45]. Overproduction or under-removal of free radicals could overpower the body’s antioxidant mechanisms and develop several adverse effects commonly seen in T2DM, such as neuropathy, retinopathy, nephropathy, and vascular complications [46]. It is known that the SOD enzyme is regarded as the first line of defense against ROS-mediated cell disruptions by catalyzing superoxide radicals to molecular oxygen and peroxide [47]. However, CAT has a prime role in regulating the cellular level of hydrogen peroxide, and its catabolism protects the cells from oxidative assaults. In fact, CAT deficiency has been suggested to predispose to progressive pancreatic β-cell failure and diabetes [48]. GSH is a thiol-containing compound known to play a crucial role in scavenging hydroxyl radicals and singlet oxygen [49]. In our experiment, treatment with TUDCA reduced SOD, CAT, and GSH in the pancreas and restored the MDA level, suggesting a decrease in lipid peroxidation. Recent studies, consistent with our results, have reported that TUDCA can increase SOD activity and other antioxidants in isolated cardiomyocytes [50], retinal degeneration models [51], and spinal cord injury in mice [52]. Through the activation of Nrf2 antioxidant signaling in the human neuroblastoma SH-SY5Y cell line, TUDCA triggered the upregulation of antioxidant enzymes, which inhibit ROS accumulation and slow down destructive damage induced by oxidative stress [53].
Inflammatory conditions are associated with increased cellular levels of ROS/RNS and the production of proinflammatory molecules [54,55]. Thus, the anti-inflammatory effect of TUDCA may be related to its excellent free radical scavenging ability and antioxidant properties. Previous in vitro data obtained using cell cultures indicate that TUDCA suppressed proinflammatory stimuli induced by nitrite production [56]. Furthermore, following proinflammatory stimuli in glial cells, TUDCA has been reported to induce the transcriptional and translational inhibition of iNOS [57], whose expression is regulated by the NFκB pathway. Consistent with these studies, we have shown that TUDCA inhibited the downstream inflammatory cascade manifested by decreasing the mRNA expression of iNOS and the levels of TNF-α, IL-6, IL-1ß, and PGE-2 in diabetic rats.
Studies have strongly pointed to increased pancreatic β-cell apoptosis in diabetes mellitus, which occurs due to the involvement of oxidative stress and inflammation [58]. In the present study, the data confirmed the upregulation of proapoptotic genes such as p53 and caspase-3 in diabetic rats, which are in agreement with previously reported studies [59,60]. Following ROS insult, elevated levels of p53 promote Bax-induced cytochrome c release and stimulate the intrinsic (mitochondrial) apoptotic pathway, with subsequent activation of caspase-3, a key effector in the execution phase of apoptotic events [61]. On the other hand, high levels of NO can interact with superoxide anion to form a potent oxidant peroxynitrite, inducing apoptotic DNA fragmentation and p53-dependent apoptosis in pancreatic islets [62]. Interestingly, we found that TUDCA treatment decreased apoptosis in the pancreas, as seen with significant decreases in the mRNA expression of iNOS, p53, and caspase-3. Consistently, previous studies also reported the anti-apoptotic effects of TUDCA in apoptosis-related diseases [63,64]. In other injury models, UDCA, and its amidated conjugates, TUDCA and glycoursodeoxycholic acid, were shown to inhibit apoptosis by reducing ROS, inhibiting Bax translocation, and, consequently, cytochrome c release, with further blockage of caspase-3 (for review, see ref. [65]).
To further assess the in vivo antidiabetic action of TUDCA, we recommend examining histopathologic findings in the pancreatic islets. The lack of details regarding the time/dose-effect relationship of TUDCA on STZ-induced T2DM is among the limitations of this experiment, and future studies should adopt more TUDCA doses at different time intervals. In future, researchers should also investigate other molecular targets of TUDCA that may play a role in alleviating oxidative stress in the pancreas during experimental diabetes.
Overall, this study introduces new information on the therapeutic role of TUDCA against T2DM (Figure 7). Based on our observations, the antihyperglycemic effects of TUDCA were accompanied by an increase in the levels of incretin GLP-1 and a decrease in CS activity. Treatment of diabetic rats with TUDCA could stabilize the intracellular redox status and prevent oxidative degradation in the pancreas. The anti-inflammatory effects of TUDCA may be related to the reduction in circulating proinflammatory proteins and cytokines and could result from boosting the antioxidant system and inhibiting iNOS-derived NO production. In addition, we provided experimental evidence that TUDCA possessed anti-apoptotic activity by downregulating the expression of P53 and caspase-3 in the diabetic pancreas. These findings therefore validate the claims that TUDCA is a promising intervention to control the diabetic milieu.

4. Materials and Methods

4.1. Chemicals

STZ was purchased from Sigma-Aldrich Chemical Co. (www.sigmaldrich.com), St. Louis, MO, USA. TUDCA was obtained commercially from Double Wood LCC, Philadelphia, PA, USA. All the other chemicals and reagents used in this study were of the highest analytical grade commercially available.

4.2. Animals

Adult male Wistar albino rats (180–200 g) were obtained from the animal breeding house at the Faculty of Agriculture, Alexandria University, Egypt. Upon delivery, the rats were kept at 22–25 °C, low relative humidity, and a 12 h light/dark cycle with standard balanced feed and tap water available ad libitum. They were accustomed to the lab conditions for 2 weeks prior to the study procedure. The animal experiments were approved by the animal care committee at Alexandria University (AU-IACUC Ref. No.: 04 22 02 12 1 02).

4.3. Experimental Design and Sample Collection

The diabetic model was induced through a single i.p. injection of low-dose STZ (40 mg/kg b.w.), which was freshly prepared with sodium citrate buffer (0.1 M/L; pH 4.5) [66]. The STZ-injected animals received a glucose solution (20%) for 24 h to prevent STZ-induced initial hypoglycemia. A total of 72 h after STZ injection, tail blood was taken to determine the glucose level using a glucometer (Frankenberg, Germany) and reagent strips (Accu-Chek, Roche, Basel, Switzerland). Rats with a fasting blood glucose level of more than 200 mg/dL were selected for further experimentation. The rats were randomly divided into three groups (with five rats in each group), as follows: nondiabetic control (Ctrl), STZ (diabetic Ctrl), and STZ+TUDCA. TUDCA treatments (300 mg/kg b.w. dissolved in sterile PBS) were started after the induction of diabetes, and this was continued for 15 days [25]. Meanwhile, the rats in the control group received the same volume of vehicle(s) as the STZ- and STZ+TUDCA-treated animals (Figure 8). At the end of the experiment, the rats were deprived of food overnight and sacrificed after light ether anesthesia. The blood was allowed to clot in a centrifuge tube and the sera were centrifuged at 3000× g (Hettich Zentrifugen, Universal 32 R, Darmstadt, Germany) for 5 min at 4 °C. The serum was separated and stored at −20 °C pending biochemical analyses. Organs (liver, muscle, and pancreas) were obtained and prepared for further assays. The remaining parts of the pancreatic tissues were immediately submerged in liquid nitrogen and kept at −80 °C for molecular testing (qRT-PCR).

4.4. Evaluation of Serum Glycemic Markers

Blood glucose was determined using an enzymatic colorimetric method according to Trinder [67]. Insulin was measured using an immunosorbent assay kit (The Thermo Scientific™ Pierce™, Waltham, MA, USA) with the intra-assay coefficient of variation percent (CV%) < 10% and the inter-assay CV% < 12%. Insulin resistance (IR) was determined by calculating the homeostatic model assessment (HOMA)-IR index, as follows: HOMA-IR = [fasting blood glucose (mg/dL) × fasting insulin (mU/mL)]/405 [68]. HbA1c% was estimated using the fast ion-exchange resin separation method [69].

4.5. Assays for Incretin GLP-1 Level and CS Activity in Serum and Glycogen Quantification in Liver and Muscle

The serum incretin GLP-1 was assessed using the Mouse/Rat Glucagon-Like Peptide-1 (GLP-1 Active) ELISA Kit (Cat. Number: RSHAKMGP-011R, Shibayagi Co., Ltd., Gunma, Japan) according to the manufacturer’s instructions, with the intra-assay and inter-assay precision CV% < 5%. Rat CS activity was determined using an ELISA Kit (Cat. Number: SL1542Ra, SunLong Biotech Co., Ltd., Hangzhou, China). The intra-assay CV% for this test, as reported by the manufacturer, was <10% and the inter-assay CV% was <12%. The liver and muscle glycogen content was determined using the method of Huijing [70].

4.6. Quantitative Evaluation of Serum Lipids

The levels of TC, TG, and HDL-C were measured in the serum samples using the methods described, respectively, by Allain [71], Bucolo and David [72], and Lopez-Virella et al. [73]. The VLDL-C and LDL-C concentrations were calculated using Friedewald formulas: VLDL-C (mg/dL) = TG/5 and LDL-C (mg/dL) = TC − (HDL-C + VLDL-C) [74].

4.7. Detection of Serum Inflammatory Response

The serum levels of TNF-α, IL-6, IL-1β, and PGE-2 were measured using commercially available ELISA kits [TNF-α: Cat. Number: RK00029, Abclonal Co., Woburn, MA, USA; IL-6: Cat. Number: MBS726707, MyBioSource; IL-1β: Cat. Number: SEA563Ca, Cloud Clone Corp.; PGE-2: Cat. Code: RTFI01386, Assay Genie Co., Tokyo, Japan]. The intra-assay and inter-assay CV% were <10% and <15% for TNF-α, 7.2–7.8% and 5.5–6.3% for IL-6, <10% and <12% for IL-1β, and <8% and <10% for PGE-2, respectively, according to the corresponding manufacturer’s protocol.

4.8. Estimation of Oxidative Stress Biomarkers in the Pancreas

The tissues were removed, weighed, and washed in ice-cold normal saline, followed by homogenization in 2 mL phosphate buffered saline (w/v: 500 mg of tissue with 4 mL of PBS, pH: 7.4). The homogenates were centrifuged at 10,000× g for 20 min at 4 °C. The supernatant was collected in clean tubes and stored at −20 °C until the assays were performed. The tissue SOD activity was estimated using the method described by Nishikimi et al. [75], while the enzymatic activity of CAT was evaluated as described by Aebi [76]. The GSH level was determined according to the method of Beutler et al. [77]. The tissue NO was colorimetrically detected as nitrite according to the Griess reaction [78]. The lipid peroxidation index (MDA) was measured by monitoring the formation of reactive thiobarbituric acid substances [79].

4.9. Quantitative Real-Time PCR (qRT-PCR) Assay

Homogenization of 50–500 mg pancreas tissues in 1 mL of Lysis buffer (easy-BLUETM reagent) (iNtRON Biotechnology, Seongnam-si, Republic of Korea) was performed, and then the total RNA was extracted using a GENEzolTM reagent Total RNA Extraction Kit (Cat. Number: GZR050, Geneaid, New Taipei City, Taiwan) as indicated in the manufacturer’s datasheet. The RNA purity and concentration were then measured using a Genova Nano Micro-Spectrophotometer (JENWAY, London, UK). From the total RNA, cDNA synthesis was performed using a TOPscriptTM cDNA synthesis kit (Cat. Number: EZ0055, Enzynomics, Daejeon, Republic of Korea). To dissolve the dried pellet, vortexing was applied. Incubation was then carried out at 42 °C for 60 min, followed by heat inactivation at 95 °C for 5 min to inactivate the reaction. For real-time quantitative PCR, reactions were conducted in a volume of 10 μL using the TOPrealTM qPCR 2X PreMIX (SYBR Green with low ROX) kit (Cat. Number: RT500, Enzynomics, Republic of Korea). PCR was carried out using AZURE CIELO real-time PCR (Azure biosystems, Dublin, CA, USA), as follows: denaturation (1 cycle): 95 °C for 10 min elongation (45 cycles): 95 °C for 15 s, 52 °C for 30 s, 72 °C for 30 s, final extension: 72 °C for 7 min. The primer sequences for the cDNA used to amplify the target genes (i.e., iNOS, P53, and caspase-3) are presented in Table 1. The relative amount of gene expression was estimated according to Livak and Schmittgen [80]:
Fold change = 2−∆∆Ct
whereas:
  • ∆∆Ct = ∆Ct reference − ∆Ct target gene
  • Ct = the cycle at threshold level
  • reference = GAPDH.
Table 1. Primers used for qRT-PCR in this study.
Table 1. Primers used for qRT-PCR in this study.
GeneForward Primer (5′->3′)Reverse Primer (5′->3′)GenBank Accession Number
iNOSGACTGCACAGAATGTTCCAGTGGCCAGATGTTCCTCTATTNM_012611
P53TAACAGTTCCTGCATGGGCGGCAGGACAGGCACAAACACGCACCNM_030989
Caspase-3AGTTGGACCCACCTTGTGAGAGTCTGCAGCTCCTCCACATNM_012922
GAPDHGGTGAAGGTCGGTGT GAACGCTCG CTCCTGGAAGATGGTGNM_017008

4.10. Statistical Analysis

The data were statistically analyzed using the IBM SPSS software package version 22.0 (Armonk, NY, USA: IBM Corp). The one-way ANOVA test was used for comparison between more than two groups, and the post hoc test (Tukey HSD) was used for pairwise comparisons. Normal distribution of the data was pre-verified using the Shapiro–Wilk test and the Kolmogorov–Smirnov test. The results are presented as the mean ± standard deviation (SD), and statistical significance was set at p < 0.05.

Author Contributions

Conceptualization, N.A.M. and A.I.E.; methodology, N.A.M., M.T.I., A.I.E. and S.A.S.; software, S.A.S.; validation, N.A.M., M.T.I., A.I.E. and S.A.S.; formal analysis, N.A.M., M.T.I., A.I.E. and S.A.S.; investigation, N.A.M., M.T.I., A.I.E. and S.A.S.; resources, M.T.I.; data curation, N.A.M., M.T.I., A.I.E. and S.A.S.; writing—original draft preparation, N.A.M., M.T.I., A.I.E. and S.A.S.; writing—review and editing, N.A.M., M.T.I., A.I.E. and S.A.S.; visualization, S.A.S.; supervision, N.A.M. and A.I.E. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Animal Care and Use Committee (ALEXU-IACUC) at Alexandria University, Egypt (AU-IACUC Ref. No.: 04 22 02 12 1 02).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting the findings of this study are available in this manuscript. All the other data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

CAT: catalase; CS: ceramide synthase; GLP-1: glucagon-like peptide-1; GSH: reduced glutathione; HbA1c%: glycosylated hemoglobin; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment for insulin resistance; IL-1ß: interleukin-1beta; IL-6: interleukin-6; iNOS: inducible nitric oxide synthase; LDL-C: low-density lipoprotein cholesterol; MDA: malondialdehyde; NO: nitric oxide; p53: tumor suppressor gene; PGE-2: prostaglandin-2; RNS: reactive nitrogen species; ROS: reactive oxygen species; SOD: superoxide dismutase; STZ: streptozotocin; TC: total cholesterol; TG: triglyceride; TNF-α: tumor necrosis factor-alpha; T2DM: type 2 diabetes mellitus; TUDCA: tauroursodeoxycholic acid; VLDL-C: very low-density lipoprotein cholesterol.

References

  1. Mohamed, N.A.; Ithmil, M.T.; Elkady, A.I.; Abdel Salam, S. Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis. Int. J. Mol. Sci. 2024, 25, 6922. [Google Scholar] [CrossRef]
  2. Wu, Y.; Ding, Y.; Tanaka, Y.; Zhang, W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int. J. Med. Sci. 2014, 11, 1185–1200. [Google Scholar] [CrossRef] [PubMed]
  3. Farmaki, P.; Damaskos, C.; Garmpis, N.; Garmpi, A.; Savvanis, S.; Diamantis, E. Complications of the type 2 diabetes mellitus. Curr. Cardiol. Rev. 2020, 16, 249–251. [Google Scholar] [CrossRef] [PubMed]
  4. Oguntibeju, O.O. Type 2 diabetes mellitus, oxidative stress and inflammation: Examining the links. Int. J. Physiol. Pathophysiol. Pharmacol. 2019, 11, 45–63. Available online: http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6628012/ (accessed on 29 April 2024). [PubMed]
  5. Kaneto, H.; Katakami, N.; Matsuhisa, M.; Matsuoka, T.-A. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat. Inflamm. 2010, 2010, 453892. [Google Scholar] [CrossRef] [PubMed]
  6. Lazaridis, K.N.; Gores, G.J.; Lindor, K.D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J. Hepatol. 2001, 35, 134–146. [Google Scholar] [CrossRef] [PubMed]
  7. Vang, S.; Longley, K.; Steer, C.J.; Low, W.C. The Unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob. Adv. Health Med. 2014, 3, 58–69. [Google Scholar] [CrossRef] [PubMed]
  8. Rodrigues, C.M.; Solá, S.; Nan, Z.; Castro, R.E.; Ribeiro, P.S.; Low, W.C.; Steer, C.J. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc. Natl. Acad. Sci. USA 2003, 100, 6087–6092. [Google Scholar] [CrossRef] [PubMed]
  9. Gaspar, J.M.; Martins, A.; Cruz, R.; Rodrigues, C.M.; Ambrósio, A.F.; Santiago, A.R. Tauroursodeoxycholic acid protects retinal neural cells from cell death induced by prolonged exposure to elevated glucose. Neuroscience 2013, 253, 380–388. [Google Scholar] [CrossRef]
  10. Zangerolamo, L.; Vettorazzi, J.F.; Solon, C.; Bronczek, G.A.; Engel, D.F.; Kurauti, M.A.; Soares, G.M.; Rodrigues, K.S.; Velloso, L.A.; Boschero, A.C.; et al. The bile acid TUDCA improves glucose metabolism in streptozotocin-induced Alzheimer’s disease mice model. Mol. Cell. Endocrinol. 2021, 521, 111116. [Google Scholar] [CrossRef]
  11. Kumar, D.; Tandon, R.K. Use of ursodeoxycholic acid in liver diseases. J. Gastroenterol. Hepatol. 2001, 16, 3–14. [Google Scholar] [CrossRef]
  12. Levy, C.; Lindor, K.D. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 2003, 38, 24–37. [Google Scholar] [CrossRef]
  13. Rodrigues, C.M.; Spellman, S.R.; Solá, S.; Grande, A.W.; Linehan-Stieers, C.; Low, W.C.; Steer, C.J. Neuroprotection by a bile acid in an acute stroke model in the rat. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2002, 22, 463–471. [Google Scholar] [CrossRef]
  14. Rivard, A.L.; Steer, C.J.; Kren, B.T.; Rodrigues, C.M.; Castro, R.E.; Bianco, R.W.; Low, W.C. Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am. J. Chin. Med. 2007, 35, 279–295. [Google Scholar] [CrossRef]
  15. Çolak, A.; Kelten, B.; Sağmanligil, A.; Akdemir, O.; Karaoğlan, A.; Şahan, E.; Çelik, Ö.; Barut, Ş. Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2008, 15, 665–671. [Google Scholar] [CrossRef]
  16. Gao, X.; Fu, L.; Xiao, M.; Xu, C.; Sun, L.; Zhang, T.; Zheng, F.; Mei, C. The nephroprotective effect of tauroursodeoxycholic acid on ischaemia/reperfusion-induced acute kidney injury by inhibiting endoplasmic reticulum stress. Basic Clin. Pharmacol. Toxicol. 2012, 111, 14–23. [Google Scholar] [CrossRef]
  17. Gupta, S.; Li, S.; Abedin, M.J.; Noppakun, K.; Wang, L.; Kaur, T.; Najafian, B.; Rodrigues, C.M.; Steer, C.J. Prevention of acute kidney injury by tauroursodeoxycholic acid in rat and cell culture models. PLoS ONE 2012, 7, e48950. [Google Scholar] [CrossRef]
  18. Üner, A.K.; Okan, A.; Akyüz, E.; Köklü, B.; Eroğlu, E.; Yilmaz, S.; Ünalmiş, D.; Kaymak, E.; Aslan, F.Ş.; Qureshi, M.Z.; et al. Tauroursodeoxycholic acid (TUDCA) regulates inflammation and hypoxia in autonomic tissues of rats with seizures. Cell. Mol. Biol. 2023, 68, 104–111. [Google Scholar] [CrossRef]
  19. Arokiyaraj, S.; Balamurugan, R.; Augustian, P. Antihyperglycemic effect of Hypericum perforatum ethyl acetate extract on streptozotocin-induced diabetic rats. Asian Pac. J. Trop. Biomed. 2011, 1, 386–390. [Google Scholar] [CrossRef]
  20. Eliza, J.; Daisy, P.; Ignacimuthu, S.; Duraipandiyan, V. Antidiabetic and antilipidemic effect of eremanthin from Costus speciosus (Koen.) Sm., in STZ-induced diabetic rats. Chem.-Biol. Interact. 2009, 182, 67–72. [Google Scholar] [CrossRef]
  21. Toma, A.; Makonnen, E.; Mekonnen, Y.; Debella, A.; Adisakwattana, S. Antidiabetic activities of aqueous ethanol and n-butanol fraction of Moringa stenopetala leaves in streptozotocin-induced diabetic rats. BMC Complement. Altern. Med. 2015, 15, 242. [Google Scholar] [CrossRef] [PubMed]
  22. AlTamimi, L.; Zakaraya, Z.Z.; Hailat, M.; Ahmad, M.N.; Qinna, N.A.; Hamad, M.F.; Dayyih, W.A. Test of insulin resistance in nondiabetic and streptozotocin-induced diabetic rats using glycosylated hemoglobin test and other interventions. J. Adv. Pharm. Technol. Res. 2024, 15, 1–7. [Google Scholar] [CrossRef] [PubMed]
  23. Simmons, R.A. Developmental origins of diabetes: The role of oxidative stress. Free. Radic. Biol. Med. 2006, 40, 917–922. [Google Scholar] [CrossRef] [PubMed]
  24. Ozcan, U.; Yilmaz, E.; Ozcan, L.; Furuhashi, M.; Vaillancourt, E.; Smith, R.O.; Gorgun, C.Z.; Hotamisligil, G.S. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006, 313, 1137–1140. [Google Scholar] [CrossRef] [PubMed]
  25. Vettorazzi, J.F.; Kurauti, M.A.; Soares, G.M.; Borck, P.C.; Ferreira, S.M.; Branco, R.C.S.; Michelone, L.D.S.L.; Boschero, A.C.; Junior, J.M.C.; Carneiro, E.M. Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice. Sci. Rep. 2017, 7, 14876. [Google Scholar] [CrossRef] [PubMed]
  26. da Silva, J.A., Jr.; Figueiredo, L.S.; Chaves, J.O.; Oliveira, K.M.; Carneiro, E.M.; Abreu, P.A.; Ribeiro, R.A. Effects of tauroursodeoxycholic acid on glucose homeostasis: Potential binding of this bile acid with the insulin receptor. Life Sci. 2021, 285, 120020. [Google Scholar] [CrossRef] [PubMed]
  27. Boer, G.A.; Holst, J.J. Incretin Hormones and type 2 diabetes-mechanistic insights and therapeutic approaches. Biology 2020, 9, 473. [Google Scholar] [CrossRef]
  28. Goldspink, D.A.; Lu, V.B.; Billing, L.J.; Larraufie, P.; Tolhurst, G.; Gribble, F.M.; Reimann, F. Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. Mol. Metab. 2018, 7, 90–101. [Google Scholar] [CrossRef]
  29. Nielsen, S.; Svane, M.S.; Kuhre, R.E.; Clausen, T.R.; Kristiansen, V.B.; Rehfeld, J.F.; Holst, J.J.; Madsbad, S.; Bojsen-Moller, K.N. Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. Physiol. Rep. 2017, 5, e13140. [Google Scholar] [CrossRef]
  30. Kuhre, R.E.; Albrechtsen, N.J.W.; Larsen, O.; Jepsen, S.L.; Balk-Møller, E.; Andersen, D.B.; Deacon, C.F.; Schoonjans, K.; Reimann, F.; Gribble, F.M.; et al. Bile acids are important direct and indirect regulators of the secretion of appetite- and metabolism-regulating hormones from the gut and pancreas. Mol. Metab. 2018, 11, 84–95. [Google Scholar] [CrossRef]
  31. El-Kordy, E.A.; Alshahrani, A.M. Effect of genistein, a natural soy isoflavone, on pancreatic β-cells of streptozotocin-induced diabetic rats: Histological and immunohistochemical study. J. Microsc. Ultrastruct. 2015, 3, 108–119. [Google Scholar] [CrossRef]
  32. Yadav, S.K.; Nagori, B.P.; Desai, P.K. Pharmacological characterization of different fractions of Calotropis procera (Asclepiadaceae) in streptozotocin induced experimental model of diabetic neuropathy. J. Ethnopharmacol. 2014, 152, 349–357. [Google Scholar] [CrossRef] [PubMed]
  33. Altura, B.M.; Shah, N.C.; Shah, G.; Zhang, A.; Li, W.; Zheng, T.; Perez-Albela, J.L.; Altura, B.T. Short-term magnesium deficiency upregulates ceramide synthase in cardiovascular tissues and cells: Cross-talk among cytokines, Mg2+, NF-κB, and de novo ceramide. Am. J. Physiol. Heart Circ. Physiol. 2012, 302, H319–H332. [Google Scholar] [CrossRef]
  34. Mandal, N.; Grambergs, R.; Mondal, K.; Basu, S.K.; Tahia, F.; Dagogo-Jack, S. Role of ceramides in the pathogenesis of diabetes mellitus and its complications. J. Diabetes Its Complicat. 2021, 35, 107734. [Google Scholar] [CrossRef] [PubMed]
  35. Boslem, E.; Meikle, P.J.; Biden, T.J. Roles of ceramide and sphingolipids in pancreatic β-cell function and dysfunction. Islets 2012, 4, 177–187. [Google Scholar] [CrossRef] [PubMed]
  36. Galadari, S.; Rahman, A.; Pallichankandy, S.; Galadari, A.; Thayyullathil, F. Role of ceramide in diabetes mellitus: Evidence and mechanisms. Lipids Health Dis. 2013, 12, 98. [Google Scholar] [CrossRef]
  37. Huang, W.C.; Chen, C.L.; Lin, Y.S.; Lin, C.F. Apoptotic sphingolipid ceramide in cancer therapy. J. Lipids 2011, 2011, 565316. [Google Scholar] [CrossRef]
  38. Novgorodov, S.A.; Gudz, T.I. Ceramide and mitochondria in ischemia/reperfusion. J. Cardiovasc. Pharmacol. 2009, 53, 198–208. [Google Scholar] [CrossRef] [PubMed]
  39. Oh, Y.S.; Bae, G.D.; Baek, D.J.; Park, E.Y.; Jun, H.S. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front. Endocrinol. 2018, 9, 384. [Google Scholar] [CrossRef]
  40. Liu, Z.; Xia, Y.; Li, B.; Xu, H.; Wang, C.; Liu, Y.; Li, Y.; Li, C.; Gao, N.; Li, L. Induction of ER stress-mediated apoptosis by ceramide via disruption of ER Ca2+ homeostasis in human adenoid cystic carcinoma cells. Cell Biosci. 2014, 4, 71. [Google Scholar] [CrossRef]
  41. Arabshomali, A.; Bazzazzadehgan, S.; Mahdi, F.; Shariat-Madar, Z. Potential benefits of antioxidant phytochemicals in type 2 diabetes. Molecules 2023, 28, 7209. [Google Scholar] [CrossRef] [PubMed]
  42. Cui, N.; Zhang, W.; Su, F.; Zhang, Z.; Qiao, W.; Sun, Y.; Yang, B.; Kuang, H.; Wang, Q. Metabolomics and lipidomics study unveils the impact of tauroursodeoxycholic acid on hyperlipidemic mice. Molecules 2023, 28, 6352. [Google Scholar] [CrossRef] [PubMed]
  43. Balasubashini, M.S.; Rukkumani, R.; Viswanathan, P.; Menon, V.P. Ferulic acid alleviates lipid peroxidation in diabetic rats. Phytother. Res. 2004, 18, 310–314. [Google Scholar] [CrossRef] [PubMed]
  44. Pillon, N.J.; Vella, R.E.; Soulère, L.; Becchi, M.; Lagarde, M.; Soulage, C.O. Structural and functional changes in human insulin induced by the lipid peroxidation byproducts 4-hydroxy-2-nonenal and 4-hydroxy-2-hexenal. Chem. Res. Toxicol. 2011, 24, 752–762. [Google Scholar] [CrossRef] [PubMed]
  45. Tangvarasittichai, S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J. Diabetes 2015, 6, 456–480. [Google Scholar] [CrossRef] [PubMed]
  46. Caturano, A.; D’Angelo, M.; Mormone, A.; Russo, V.; Mollica, M.P.; Salvatore, T.; Galiero, R.; Rinaldi, L.; Vetrano, E.; Marfella, R.; et al. Oxidative stress in type 2 diabetes: Impacts from pathogenesis to lifestyle modifications. Curr. Issues Mol. Biol. 2023, 45, 6651–6666. [Google Scholar] [CrossRef] [PubMed]
  47. Tiwari, B.K.; Pandey, K.B.; Abidi, A.B.; Rizvi, S.I. Markers of oxidative stress during diabetes mellitus. J. Biomark. 2013, 2013, 378790. [Google Scholar] [CrossRef] [PubMed]
  48. Góth, L.; Eaton, J.W. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 2000, 356, 1820–1821. [Google Scholar] [CrossRef] [PubMed]
  49. Tuell, D.; Ford, G.; Los, E.; Stone, W. The Role of glutathione and its precursors in type 2 diabetes. Antioxidants 2024, 13, 184. [Google Scholar] [CrossRef]
  50. Zhang, L.; Wang, Y. Tauroursodeoxycholic acid alleviates H2O2-induced oxidative stress and apoptosis via suppressing endoplasmic reticulum stress in neonatal rat cardiomyocytes. Dose-Response 2018, 9, 1559325818782631. [Google Scholar] [CrossRef]
  51. Alhasani, R.H.; Almarhoun, M.; Zhou, X.; Reilly, J.; Patterson, S.; Zeng, Z.; Shu, X. Tauroursodeoxycholic acid protects retinal pigment epithelial cells from oxidative injury and endoplasmic reticulum stress in vitro. Biomedicines 2020, 8, 367. [Google Scholar] [CrossRef] [PubMed]
  52. Hou, Y.; Luan, J.; Huang, T.; Deng, T.; Li, X.; Xiao, Z.; Zhan, J.; Luo, D.; Hou, Y.; Xu, L.; et al. Tauroursodeoxycholic acid alleviates secondary injury in spinal cord injury mice by reducing oxidative stress, apoptosis, and inflammatory response. J. Neuroinflamm. 2021, 18, 216. [Google Scholar] [CrossRef] [PubMed]
  53. Moreira, S.; Fonseca, I.; Nunes, M.J.; Rosa, A.; Lemos, L.; Rodrigues, E.; Carvalho, A.N.; Outeiro, T.F.; Rodrigues, C.M.P.; Gama, M.J.; et al. Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson’s disease. Exp. Neurol. 2017, 295, 77–87. [Google Scholar] [CrossRef] [PubMed]
  54. Keane, K.N.; Cruzat, V.F.; Carlessi, R.; de Bittencourt, P.I.H.; Newsholme, P. Molecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunction. Oxidative Med. Cell. Longev. 2015, 2015, 181643. [Google Scholar] [CrossRef]
  55. Busa, P.; Kuthati, Y.; Huang, N.; Wong, C.S. New Advances on pathophysiology of diabetes neuropathy and pain management: Potential role of melatonin and DPP-4 inhibitors. Front. Pharmacol. 2022, 13, 864088. [Google Scholar] [CrossRef]
  56. Kim, S.J.; Ko, W.K.; Jo, M.J.; Arai, Y.; Choi, H.; Kumar, H.; Han, I.B.; Sohn, S. Anti-inflammatory effect of Tauroursodeoxycholic acid in RAW 264.7 macrophages, Bone marrow-derived macrophages, BV2 microglial cells, and spinal cord injury. Sci. Rep. 2018, 8, 3176. [Google Scholar] [CrossRef] [PubMed]
  57. Yanguas-Casás, N.; Barreda-Manso, M.A.; Nieto-Sampedro, M.; Romero-Ramírez, L. Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. J. Neuroinflamm. 2014, 11, 50. [Google Scholar] [CrossRef] [PubMed]
  58. Dludla, P.V.; Mabhida, S.E.; Ziqubu, K.; Nkambule, B.B.; Mazibuko-Mbeje, S.E.; Hanser, S.; Basson, A.K.; Pheiffer, C.; Kengne, A.P. Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J. Diabetes 2023, 14, 130–146. [Google Scholar] [CrossRef]
  59. Peng, J.; Li, X.; Zhang, D.; Chen, J.K.; Su, Y.; Smith, S.B.; Dong, Z. Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 2015, 87, 137–150. [Google Scholar] [CrossRef]
  60. Kung, C.P.; Murphy, M.E. The role of the p53 tumor suppressor in metabolism and diabetes. J. Endocrinol. 2016, 231, R61–R75. Available online: https://pubmed.ncbi.nlm.nih.gov/?term=Murphy+ME&cauthor_id=27613337 (accessed on 29 April 2024). [CrossRef]
  61. Redza-Dutordoir, M.; Averill-Bates, D.A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys. Acta (BBA)-Mol. Cell Res. 2016, 1863, 2977–2992. [Google Scholar] [CrossRef] [PubMed]
  62. Kim, Y.-M.; Bombeck, C.A.; Billiar, T.R. Nitric oxide as a bifunctional regulator of apoptosis. Circ. Res. 1999, 84, 253–256. [Google Scholar] [CrossRef] [PubMed]
  63. Khalaf, K.; Tornese, P.; Cocco, A.; Albanese, A. Tauroursodeoxycholic acid: A potential therapeutic tool in neurodegenerative diseases. Transl. Neurodegener. 2022, 11, 33. [Google Scholar] [CrossRef] [PubMed]
  64. Song, G.; Weng, F.; Zou, B.; Zhao, J.; Jin, J.; Yan, D.; Huang, K.; Sun, X.; Liu, C.; Hu, Y.; et al. Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr/Nrf2 and CHOP-DR5-caspase-8 pathway. Clin. Sci. 2023, 137, 561–577. [Google Scholar] [CrossRef] [PubMed]
  65. Amaral, J.D.; Viana, R.J.S.; Ramalho, R.M.; Steer, C.J.; Rodrigues, C.M.P. Bile acids: Regulation of apoptosis by ursodeoxycholic acid. J. Lipid Res. 2009, 50, 1721–1734. [Google Scholar] [CrossRef]
  66. Aloud, A.A.; Veeramani, C.; Govindasamy, C.; Alsaif, M.A.; El Newehy, A.S.; Al-Numair, K.S. Galangin, a dietary flavonoid, improves antioxidant status and reduces hyperglycemia-mediated oxidative stress in streptozotocin-induced diabetic rats. Redox Rep. Commun. Free. Radic. Res. 2017, 22, 290–300. [Google Scholar] [CrossRef]
  67. Trinder, P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J. Clin. Pathol. 1969, 22, 158–161. [Google Scholar] [CrossRef]
  68. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28, 412–419. [Google Scholar] [CrossRef]
  69. Nathan, D.M.; Singer, D.E.; Hurxthal, K.; Goodson, J.D. The clinical information value of the glycosylated hemoglobin assay. N. Engl. J. Med. 1984, 310, 341–346. [Google Scholar] [CrossRef]
  70. Huijing, F. A rapid enzymic method for glycogen estimation in very small tissue samples. Clin. Chim. Acta Int. J. Clin. Chem. 1970, 30, 567–572. [Google Scholar] [CrossRef]
  71. Allain, C.C.; Poon, L.S.; Chan, C.S.; Richmond, W.F.P.C.; Fu, P.C. Enzymatic determination of total serum cholesterol. Clin. Chem. 1974, 20, 470–475. [Google Scholar] [CrossRef] [PubMed]
  72. Bucolo, G.; David, H. Quantitative determination of serum triglycerides by the use of enzymes. Clin. Chem. 1973, 19, 476–482. [Google Scholar] [CrossRef] [PubMed]
  73. Lopes-Virella, M.F.; Stone, P.; Ellis, S.; Colwell, J.A. Cholesterol determination in high density lipoproteins separated by three different methods. Clin. Chem. 1977, 23, 882–884. [Google Scholar] [CrossRef] [PubMed]
  74. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499–502. [Google Scholar] [CrossRef]
  75. Nishikimi, M.; Appaji Rao, N.; Yagi, K. The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen. Biochem. Biophys. Res. Commun. 1972, 46, 849–854. [Google Scholar] [CrossRef] [PubMed]
  76. Aebi, H. Catalase in vitro. Methods Enzymol. 1984, 105, 121–126. [Google Scholar] [CrossRef] [PubMed]
  77. Beutler, E.; Duron, O.; Kelly, B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61, 882–888. [Google Scholar]
  78. Montgomery, H.; Dymock, J. Determination of Nitrite in Water, Royal Soc Chemistry Thomas Graham House; Science Park, Milton Rd: Cambridge, UK, 1961. [Google Scholar]
  79. Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [Google Scholar] [CrossRef]
  80. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
Ijms 25 06922 g001
Figure 1. TUDCA decreased the levels of serum glucose (A), HbA1c% (B), and HOMA-IR (C) and increased insulin (D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 1. TUDCA decreased the levels of serum glucose (A), HbA1c% (B), and HOMA-IR (C) and increased insulin (D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g001
Ijms 25 06922 g002
Figure 2. TUDCA increased serum incretin GLP-1 (A), decreased serum CS (B), and enhanced liver/muscle glycogen storage (C,D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 2. TUDCA increased serum incretin GLP-1 (A), decreased serum CS (B), and enhanced liver/muscle glycogen storage (C,D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g002
Ijms 25 06922 g003
Figure 3. TUDCA decreased serum levels of TC (A), TG (B), LDL-C (C), and VLDL-C (D) and increased HDL-C (E) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 3. TUDCA decreased serum levels of TC (A), TG (B), LDL-C (C), and VLDL-C (D) and increased HDL-C (E) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g003
Ijms 25 06922 g004
Figure 4. TUDCA decreased serum TNF-α (A), IL-6 (B), IL-1β (C), and PGE-2 (D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 4. TUDCA decreased serum TNF-α (A), IL-6 (B), IL-1β (C), and PGE-2 (D) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g004
Ijms 25 06922 g005
Figure 5. TUDCA increased pancreatic SOD (A), CAT (B), and GSH (C) and decreased NO (D) and MDA (E) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 5. TUDCA increased pancreatic SOD (A), CAT (B), and GSH (C) and decreased NO (D) and MDA (E) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g005
Ijms 25 06922 g006
Figure 6. TUDCA downregulated pancreatic mRNA expression of iNOS (A), p53 (B), and caspase-3 (C) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 4 or 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Figure 6. TUDCA downregulated pancreatic mRNA expression of iNOS (A), p53 (B), and caspase-3 (C) in STZ-induced diabetic rats. Data are expressed as mean ± SD (n = 4 or 5). * p < 0.05 versus control (Ctrl), and # p < 0.05 versus STZ.
Ijms 25 06922 g006
Ijms 25 06922 g007
Figure 7. Schematic representation of the mechanism of action of TUDCA against the STZ-induced diabetic in vivo model. Created with BioRender.com.
Figure 7. Schematic representation of the mechanism of action of TUDCA against the STZ-induced diabetic in vivo model. Created with BioRender.com.
Ijms 25 06922 g007
Ijms 25 06922 g008
Figure 8. Timeline showing a summary of the study protocol.
Figure 8. Timeline showing a summary of the study protocol.
Ijms 25 06922 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mohamed, N.A.; Ithmil, M.T.; Elkady, A.I.; Abdel Salam, S. Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis. Int. J. Mol. Sci. 2024, 25, 6922. https://doi.org/10.3390/ijms25136922

AMA Style

Mohamed NA, Ithmil MT, Elkady AI, Abdel Salam S. Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis. International Journal of Molecular Sciences. 2024; 25(13):6922. https://doi.org/10.3390/ijms25136922

Chicago/Turabian Style

Mohamed, Nema A., Mohammed T. Ithmil, Ayman I. Elkady, and Sherine Abdel Salam. 2024. "Tauroursodeoxycholic Acid (TUDCA) Relieves Streptozotocin (STZ)-Induced Diabetic Rat Model via Modulation of Lipotoxicity, Oxidative Stress, Inflammation, and Apoptosis" International Journal of Molecular Sciences 25, no. 13: 6922. https://doi.org/10.3390/ijms25136922

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop